...
...
Next Story

TB challenge needs a multi-focal approach

The general trend of decline in incidence and mortality of TB cases are certainly encouraging. Still, drug-resistant TB needs urgent focus.

Published on: Mar 27, 2024 10:17 PM IST
By
Prefer HTon Google
Advertisement

An increase in the number of tuberculosis (TB) cases notified in India in 2023 over 2022 underscores the rigour of the efforts to shrink the pool escaping the TB control programme’s radar. The better capture of cases can be credited to the private sector’s impressive jump in performance, as well as states like Uttar Pradesh and Bihar bettering their record. With such success, a larger number of patients than earlier can be monitored for effective treatment, which, in turn, can

PREMIUMNon-lung TB is another challenging facet of India’s TB burden.  (HT PHOTO)
Non-lung TB is another challenging facet of India’s TB burden. (HT PHOTO)

An increase in the number of tuberculosis (TB) cases notified in India in 2023 over 2022 underscores the rigour of the efforts to shrink the pool escaping the TB control programme’s radar. The better capture of cases can be credited to the private sector’s impressive jump in performance, as well as states like Uttar Pradesh and Bihar bettering their record. With such success, a larger number of patients than earlier can be monitored for effective treatment, which, in turn, can curb the spread and prevent any uptick in mortality and the evolution of more menacing forms of the pathogen.

PREMIUMNon-lung TB is another challenging facet of India’s TB burden.  (HT PHOTO)
Non-lung TB is another challenging facet of India’s TB burden. (HT PHOTO)

India’s TB notification success and the general trend of decline in incidence and mortality are certainly encouraging. Even as this momentum is preserved, drug-resistant TB needs urgent focus. Though WHO data showed that the incidence of multi-drug resistant (MDR) TB in the country was on a slow-decline trajectory before the pandemic, an increase was recorded in 2021. India’s own data bears out this trend. The country reports the highest incidence of MDR TB globally. Its stance on patent applications for bedaquiline, a last resort drug, might have made it easier to produce the drug locally, but bedaquiline coverage is estimated to be much smaller than needed.

Non-lung TB is another challenging facet of India’s TB burden. This is more common in women, and manifests very differently from pulmonary TB, whose symptoms are more widely recognised in comparison — and therefore, is often missed. The problem is exacerbated by the access barriers that women face when it comes to timely care. Against such a backdrop, the TB control programme needs to adopt a multi-focal approach.

All Access.
One Subscription.

Get 360° coverage—from daily headlines
to 100 year archives.

E-Paper
Full
Archives
Full Access to
HT App & Website
Games
 
Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away! -Login Now!
Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away! -Login Now!
SHARE THIS ARTICLE ON
Hindustantimes wants to start sending you push notifications. Click allow to subscribe